Quadrant Capital Group’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-616
| Closed | -$46.3K | – | 1886 |
|
|
2026
Q1 | $46.3K | Hold |
616
| – | – | ﹤0.01% | 1731 |
|
|
2025
Q4 | $48.7K | Hold |
616
| – | – | ﹤0.01% | 1692 |
|
|
2025
Q3 | $40.3K | Buy |
+616
| New | +$30.1K | ﹤0.01% | 1745 |
|
|
2025
Q2 | – | Sell |
-381
| Closed | -$11.5K | – | 1956 |
|
|
2025
Q1 | $11.5K | Sell |
381
-705
| -65% | -$23.1K | ﹤0.01% | 2190 |
|
|
2024
Q4 | $38K | Buy |
1,086
+216
| +25% | +$8.07K | ﹤0.01% | 1568 |
|
|
2024
Q3 | $34.9K | Buy |
870
+10
| +1% | +$465 | ﹤0.01% | 1647 |
|
|
2024
Q2 | $41K | Buy |
860
+286
| +50% | +$11.7K | ﹤0.01% | 1504 |
|
|
2024
Q1 | $24.9K | Sell |
574
-97
| -14% | -$4.62K | ﹤0.01% | 1749 |
|
|
2023
Q4 | $33.9K | Buy |
671
+83
| +14% | +$3.98K | ﹤0.01% | 1574 |
|
|
2023
Q3 | $26.7K | Hold |
588
| – | – | ﹤0.01% | 1570 |
|
|
2023
Q2 | $24.1K | Sell |
588
-2
| -0.3% | -$77 | ﹤0.01% | 1629 |
|
|
2023
Q1 | $21.1K | Buy |
590
+343
| +139% | +$12.9K | ﹤0.01% | 1676 |
|
|
2022
Q4 | $9.33K | Sell |
247
-50
| -17% | -$2.1K | ﹤0.01% | 1981 |
|
|
2022
Q3 | $13K | Buy |
297
+34
| +13% | +$1.43K | ﹤0.01% | 1766 |
|
|
2022
Q2 | $10K | Sell |
263
-4
| -1% | -$151 | ﹤0.01% | 1656 |
|
|
2022
Q1 | $10K | Sell |
267
-73
| -21% | -$2.39K | ﹤0.01% | 1645 |
|
|
2021
Q4 | $10K | Sell |
340
-126
| -27% | -$3.97K | ﹤0.01% | 1624 |
|
|
2021
Q3 | $16K | Buy |
466
+408
| +703% | +$15.4K | ﹤0.01% | 1369 |
|
|
2021
Q2 | $2K | Sell |
58
-207
| -78% | -$8.11K | ﹤0.01% | 2106 |
|
|
2021
Q1 | $12K | Buy |
265
+10
| +4% | +$558 | ﹤0.01% | 1420 |
|
|
2020
Q4 | $14K | Buy |
255
+139
| +120% | +$6.93K | ﹤0.01% | 1236 |
|
|
2020
Q3 | $6K | Buy |
116
+75
| +183% | +$4.17K | ﹤0.01% | 1463 |
|
|
2020
Q2 | $2K | Sell |
41
-449
| -92% | -$25K | ﹤0.01% | 1912 |
|
|
2020
Q1 | $23K | Buy |
490
+467
| +2,030% | +$26K | ﹤0.01% | 1226 |
|
|
2019
Q4 | $1K | Sell |
23
-195
| -89% | -$11.6K | ﹤0.01% | 2325 |
|
|
2019
Q3 | $12K | Buy |
218
+195
| +848% | +$12.7K | ﹤0.01% | 1729 |
|
|
2019
Q2 | $1K | Sell |
23
-653
| -97% | -$46.2K | ﹤0.01% | 2233 |
|
|
2019
Q1 | $53K | Buy |
676
+653
| +2,839% | +$42.1K | 0.01% | 1188 |
|
|
2018
Q4 | $1K | Hold |
23
| – | – | ﹤0.01% | 2052 |
|
|
2018
Q3 | $1K | Hold |
23
| – | – | ﹤0.01% | 2010 |
|
|
2018
Q2 | $0 | Hold |
23
| – | – | ﹤0.01% | 2174 |
|
|
2018
Q1 | $1K | Hold |
23
| – | – | ﹤0.01% | 2010 |
|
|
2017
Q4 | $1K | Hold |
23
| – | – | ﹤0.01% | 1955 |
|
|
2017
Q3 | $1K | Hold |
23
| – | – | ﹤0.01% | 1967 |
|
|
2017
Q2 | $1K | Hold |
23
| – | – | ﹤0.01% | 1727 |
|
|
2017
Q1 | $0 | Hold |
23
| – | – | ﹤0.01% | 2093 |
|
|
2016
Q4 | $1K | Buy |
+23
| New | +$910 | ﹤0.01% | 1712 |
|
|
2016
Q2 | – | Sell |
-91
| Closed | -$2K | – | 2020 |
|
|
2016
Q1 | $2K | Sell |
91
-88
| -49% | -$3.57K | ﹤0.01% | 1360 |
|
|
2015
Q4 | $10K | Buy |
179
+77
| +75% | +$4.16K | 0.01% | 798 |
|
|
2015
Q3 | $3K | Hold |
102
| – | – | ﹤0.01% | 893 |
|
|
2015
Q2 | $5K | Buy |
+102
| New | +$6.49K | ﹤0.01% | 838 |
|
Other funds holding IONS
Quadrant Capital Group's IONS Position: Q2 2026 in Review
Quadrant Capital Group sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 616 shares — an estimated $46.3K sold.
Quadrant Capital Group first reported a position in IONS in Q2 2015 and held it in 41 quarters. The position peaked at $53K in Q1 2019. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- Quadrant Capital Group reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 616 Ionis Pharmaceuticals shares in Q2 2026, an estimated $46.3K.
- Quadrant Capital Group first reported a position in Ionis Pharmaceuticals in Q2 2015 and held it in 41 quarters.
- Quadrant Capital Group's Ionis Pharmaceuticals position peaked at $53K in Q1 2019.
- 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.